Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News Briefs: SGR Reform Bill Progress; CareFusion To Invest In Infusion Pump Firm

This article was originally published in The Gray Sheet

Executive Summary

House and Senate committees approve long-term physician payment reform bills. CareFusion announces it will invest $100 million in infusion pump maker Caesarea Medical Electronics. More news.

You may also be interested in...



FDA Hits Baxter With Two Warning Letters In Four Weeks

The warning letters cite quality system regulation violations related to the firm’s infusion pumps, including inadequate corrective and preventive actions related to complaints of over-infusion and device bladder ruptures.

Ban On In-Office Ancillary Exception To Stark Law For Self-Referrals Debated As Offset For Doc-Fix Bill

To help pay for the Doc-Fix bill, Rep. Jackie Speier, D-Calif. and other want to eliminate an in-office ancillary exception to self-referral regulations that lets physicians provide radiation therapy and advanced imaging services in their own offices. But several senators and medical societies are staunchly defending the Stark law exception.

Senate Approves Budget Bill, Giving Lawmakers Less Than A Month To Fund FDA, Other Agencies

The Senate voted 64-36 Dec. 18 to approve a budget deal, giving congressional appropriators less than a month to replace a continuing resolution with 2014 spending levels for FDA and other federal agencies.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel